M Martínez-Galdámez1, A Romance2, P Vega3, A Vega4, J L Caniego5, L Paul6, I Linfante7, G Dabus7. 1. Interventional Neuroradiology Unit, Hospital Clínico Univeristario de Valladolid, Valladolid, Spain. 2. Interventional Neuroradiology Unit, Hospital Carlos Haya, Málaga, Spain. 3. Interventional Neuroradiology Unit, Hospital Central de Asturias, Oviedo, Spain. 4. Interventional Neuroradiology Unit, Hospital Puerta de Hierro, Madrid, Spain. 5. Interventional Neuroradiology Unit, Hospital La Princesa, Madrid, Spain. 6. Interventional Neuroradiology Unit, Hospital de Getafe, Madrid, Spain. 7. Interventional Neuroradiology, Baptist Cardiac and Vascular Institute and Baptist Neuroscience Center, Miami, Florida, USA.
Abstract
BACKGROUND AND PURPOSE: The aim of our study was to evaluate the safety and efficacy of the pipeline endovascular device for the treatment of anterior circulation aneurysms at the level of the circle of Willis and beyond. METHODS: A consecutive series of 25 patients (24 unruptured and one ruptured) with anterior circulation aneurysms treated with a pipeline endovascular device were included in the analysis. RESULTS: We found two minor clinical events (resolved within 7 days of the procedure), one major event (symptoms present after 7 days), and no mortality. There were no aneurysm ruptures or parenchymal hemorrhages during follow-up. The modified Rankin Scale (mRS) scores at 3 and 6 months did not change from the prior mRS score for all cases except 1. There was one asymptomatic periprocedural event. There were three intraprocedural complications which resolved without clinical consequences. Six month follow-up angiograms were obtained for 22 aneurysms, showing complete occlusion in 14 (64%) and significantly decreased residual filling in 8 (36%). The status of branches originating from the aneurysm sacs was evaluated in 14 angiograms: 11 were patent (79%), 2 had moderate reduction (14%) and 1 (7%) was occluded. We found six cases of in-stent stenosis (27%) on 6 month DSA, with only one symptomatic case. CONCLUSIONS: The pipeline embolization device provides a feasible and technically safe solution for aneurysms at and beyond the circle of Willis. Preliminary results are promising but larger series with longer term follow-up examinations are required to show the long term safety and durability of this treatment alternative. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
BACKGROUND AND PURPOSE: The aim of our study was to evaluate the safety and efficacy of the pipeline endovascular device for the treatment of anterior circulation aneurysms at the level of the circle of Willis and beyond. METHODS: A consecutive series of 25 patients (24 unruptured and one ruptured) with anterior circulation aneurysms treated with a pipeline endovascular device were included in the analysis. RESULTS: We found two minor clinical events (resolved within 7 days of the procedure), one major event (symptoms present after 7 days), and no mortality. There were no aneurysm ruptures or parenchymal hemorrhages during follow-up. The modified Rankin Scale (mRS) scores at 3 and 6 months did not change from the prior mRS score for all cases except 1. There was one asymptomatic periprocedural event. There were three intraprocedural complications which resolved without clinical consequences. Six month follow-up angiograms were obtained for 22 aneurysms, showing complete occlusion in 14 (64%) and significantly decreased residual filling in 8 (36%). The status of branches originating from the aneurysm sacs was evaluated in 14 angiograms: 11 were patent (79%), 2 had moderate reduction (14%) and 1 (7%) was occluded. We found six cases of in-stent stenosis (27%) on 6 month DSA, with only one symptomatic case. CONCLUSIONS: The pipeline embolization device provides a feasible and technically safe solution for aneurysms at and beyond the circle of Willis. Preliminary results are promising but larger series with longer term follow-up examinations are required to show the long term safety and durability of this treatment alternative. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Authors: Ahmed E Hussein; Meghana Shownkeen; Andre Thomas; Christopher Stapleton; Denise Brunozzi; Jessica Nelson; John Naumgart; Andreas Linninger; Gursant Atwal; Ali Alaraj Journal: Interv Neuroradiol Date: 2020-02-26 Impact factor: 1.610
Authors: Katyucia De Macedo Rodrigues; Anna Luisa Kühn; Takamitsu Tamura; Guilherme Dabus; Peter Kan; Miklos G Marosfoi; J Diego Lozano; Mary Perras; Christopher Brooks; Mary C Howk; Samuel Y Hou; David E Rex; Francesco Massari; Matthew J Gounis; Ajay K Wakhloo; Ajit S Puri Journal: Oper Neurosurg (Hagerstown) Date: 2018-04-01 Impact factor: 2.703
Authors: M A Möhlenbruch; O Kizilkilic; M Killer-Oberpfalzer; F Baltacioglu; C Islak; M Bendszus; S Cekirge; I Saatci; N Kocer Journal: AJNR Am J Neuroradiol Date: 2017-08-10 Impact factor: 3.825
Authors: Sophia Hohenstatt; Sergio L Vinci; Dominik F Vollherbst; Agostino Tessitore; Niclas Schmitt; Antonio Pitrone; Antonio A Caragliano; Mariano Velo; Markus A Möhlenbruch; Aldo Paolucci Journal: Clin Neuroradiol Date: 2022-06-29 Impact factor: 3.649
Authors: F Clarençon; F Di Maria; J Gabrieli; E Shotar; C Zeghal; A Nouet; J Chiras; N-A Sourour Journal: Clin Neuroradiol Date: 2015-08-07 Impact factor: 3.649
Authors: Ajit S Puri; Francesco Massari; Takumi Asai; Miklos Marosfoi; Peter Kan; Samuel Y Hou; Mary Howk; Mary Perras; Christopher Brooks; Frederic Clarencon; Matthew J Gounis; Ajay K Wakhloo Journal: Neuroradiology Date: 2015-12-23 Impact factor: 2.804
Authors: Sami Al Kasab; Waldo R Guerrero; Daichi Nakagawa; Edgar A Samaniego; Santiago Ortega-Gutierrez; David Hasan Journal: Interv Neurol Date: 2019-01-16